Aikya Investment Management Ltd Has $103.03 Million Position in Dr. Reddy's Laboratories Ltd $RDY

Key Points

• Aikya Investment Management raised its stake in Dr. Reddy's by 9.3% to 7,338,525 shares (an additional 623,518 shares), worth about $103.03 million
• Analyst sentiment is mixed with an average rating of Hold and an average target price of $16.90 (1 Buy, 2 Hold, 1 Sell); notably, Goldman Sachs downgraded RDY to a Sell while Weiss Ratings nudged its view to Hold (c+).
• RDY opened at $13.73, trading in a 12‑month range of $12.77–$16.17, with a market cap of about $11.46 billion and a P/E of 17.82, while institutional ownership is reported at 3.85%.

Aikya Investment Management Ltd grew its holdings in shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY - Free Report) by 9.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,338,525 shares of the company's stock after purchasing an additional 623,518 shares during the period. Dr. Reddy's Laboratories makes up 23.4% of Aikya Investment Management Ltd's portfolio, making the stock its 3rd biggest holding. Aikya Investment Management Ltd owned 0.88% of Dr. Reddy's Laboratories worth $103,033,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. EverSource Wealth Advisors LLC boosted its holdings in shares of Dr. Reddy's Laboratories by 71.7% in the second quarter. EverSource Wealth Advisors LLC now owns 3,100 shares of the company's stock worth $47,000 after buying an additional 1,294 shares during the period. Farther Finance Advisors LLC boosted its holdings in shares of Dr. Reddy's Laboratories by 217.4% in the third quarter. Farther Finance Advisors LLC now owns 3,568 shares of the company's stock worth $50,000 after buying an additional 2,444 shares during the period. Westside Investment Management Inc. boosted its holdings in shares of Dr. Reddy's Laboratories by 94.8% in the third quarter. Westside Investment Management Inc. now owns 4,595 shares of the company's stock worth $65,000 after buying an additional 2,236 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Dr. Reddy's Laboratories in the second quarter worth about $67,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Dr. Reddy's Laboratories in the third quarter worth about $78,000. Institutional investors own 3.85% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on RDY shares. The Goldman Sachs Group lowered shares of Dr. Reddy's Laboratories from a "neutral" rating to a "sell" rating in a research report on Thursday, April 23rd. Weiss Ratings raised shares of Dr. Reddy's Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a research report on Monday, April 27th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Dr. Reddy's Laboratories presently has an average rating of "Hold" and an average target price of $16.90.

Dr. Reddy's Laboratories Trading Up 0.6%

NYSE:RDY opened at $13.73 on Friday. Dr. Reddy's Laboratories Ltd has a 12 month low of $12.77 and a 12 month high of $16.17. The firm has a market cap of $11.46 billion, a price-to-earnings ratio of 17.82, a P/E/G ratio of 21.31 and a beta of 0.27. The company has a quick ratio of 1.38, a current ratio of 1.88 and a debt-to-equity ratio of 0.03. The company's 50 day moving average is $13.80 and its 200-day moving average is $13.86.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Ltd. is an India‐based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.

The company's core activities include the development and commercialization of cost‐effective generic treatments for branded drugs that have lost patent protection, along with in‐house research into innovative molecule development.

Want to see what other hedge funds are holding RDY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dr. Reddy's Laboratories Ltd (NYSE:RDY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.